NextCell Pharma publishes Interim Report 1 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2021 - November 30, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

First quarter (2021-09-01 until 2021-11-30)

● Operating income amounted to TSEK 1 347 (1 148).
● Operating result amounted to TSEK -6 472 (-5 473).
● Earnings per share* amounted to SEK -0,19 (-0,23).
● Cash and bank amounted to TSEK 133 464 (16 810).
● Solidity** amounted to 94,1 (84,9) %.

*Result per share: operating results divided by the average number of shares. Average number of shares for the first quarter of 2021/2022 is: 34 379 523 (23 398 334) shares. Number of shares in NextCell as per November 30th 2021 is: 34 379 523 (23 398 334).
**Solidity/Equity ratio: shareholders' equity of the balance sheet total.

Significant events during the first quarter of 2021/2022

● NextCell announced in the beginning of September that three patients with Covid-19 had been treated with ProTrans in the Swedish study ProTrans19+SE conducted at Örebro University Hospital. As a result, all patients in the low-dose cohort had then been treated.

● In the beginning of October NextCell announced that their CEO, Dr. Mathias Svahn, was presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies.

● NextCell announced in the end of October an updated strategy for ProTrans clinical trial program in Type 1 diabetes that will increase the Company’s market potential and reduces its risk.

● NextCell Pharma AB announced in the end of Octoberthat the clinical trial ProTrans19+SE can commence to enroll patients in the medium dose group. Three patients having recieved a low dose ProTrans, have been clinically assessed and evaluated by the Data and Safety Monitoring Board, which allows continuation with medium dose treatment ProTrans for COVID-19 induced ser pneumonia.

Significant events after the reporting period

● In December NextCell Pharma announced a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D. The aim is together to spread hope for type 1 diabetes and make NextCell's clinical trials visible.

● NextCell announced at end of January that their CEO, Dr. Mathias Svahn was invited to give a presentation about the company journey within the cell therapy arena at the prestigious Advanced Therapy Week held in Miami, Florida from Tuesday the 25th to Friday the 28th of January.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 27-01-2022 08:00 CET.

For further information, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO

Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 10% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.